CAS 1048668-70-7: AZD8329
Description:AZD8329 is a small molecule inhibitor primarily developed for therapeutic applications in oncology, particularly targeting specific pathways involved in cancer cell proliferation and survival. It is designed to inhibit certain kinases, which play a crucial role in signaling pathways that regulate cell growth and division. The compound exhibits characteristics typical of targeted cancer therapies, including selectivity for its molecular targets, which helps minimize off-target effects and improve efficacy. AZD8329 is often evaluated in preclinical and clinical studies to assess its pharmacokinetics, bioavailability, and safety profile. Its chemical structure includes functional groups that contribute to its binding affinity and specificity for the intended targets. As with many investigational drugs, ongoing research aims to elucidate its mechanism of action, potential resistance mechanisms, and optimal therapeutic combinations. Overall, AZD8329 represents a promising candidate in the field of targeted cancer therapy, reflecting the ongoing efforts to develop more effective and personalized treatment options for patients.
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | AZD8329 REF: 54-BUP04819CAS: 1048668-70-7 | ≥98% | 947.00 €~2,226.00 € | Tue 06 May 25 |
 | AZD 8329 REF: 3D-BA179810CAS: 1048668-70-7 | Min. 95% | 379.00 €~1,023.00 € | Mon 16 Jun 25 |
 | AZD8329 REF: TM-T14383CAS: 1048668-70-7 | 99.31% | To inquire | Mon 23 Jun 25 |
Ref: 54-BUP04819
| 25mg | 947.00 € | ||
| 50mg | 1,282.00 € | ||
| 100mg | 2,226.00 € |
AZD 8329
Ref: 3D-BA179810
| 5mg | 379.00 € | ||
| 10mg | 573.00 € | ||
| 25mg | 1,023.00 € |
AZD8329
Ref: TM-T14383
| 1mg | 92.00 € | ||
| 5mg | 188.00 € | ||
| 10mg | 311.00 € | ||
| 25mg | 645.00 € | ||
| 50mg | 947.00 € | ||
| 100mg | 1,644.00 € | ||
| 1mL*10mM (DMSO) | 215.00 € |
